Rohinton Toddywala serves as the Executive Vice President of Nostrum Pharmaceuticals LLC and the Chief Technology Officer at InspiRx Inc., where he leverages over 20 years of extensive experience in pharmaceutical development and medical device innovation. As a co-founder of InspiRx, he is at the...
Rohinton Toddywala serves as the Executive Vice President of Nostrum Pharmaceuticals LLC and the Chief Technology Officer at InspiRx Inc., where he leverages over 20 years of extensive experience in pharmaceutical development and medical device innovation. As a co-founder of InspiRx, he is at the forefront of advancing respiratory therapies, focusing on a robust pipeline of inhaled drugs aimed at treating critical conditions such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Ventilator-Associated Pneumonia (VAP), Multi-Drug Resistant Tuberculosis (MDRTb), and Idiopathic Pulmonary Fibrosis (IPF). His expertise in drug delivery systems, particularly in the realm of drug-device combination products, positions him as a key player in developing innovative solutions that improve patient outcomes.
Under his leadership, InspiRx is pioneering the integration of cutting-edge technologies, including artificial intelligence (AI) and neuromodulation, to enhance the efficacy of respiratory devices. His comprehensive background in R&D, product development, and global marketing enables him to navigate the complexities of bringing novel medical solutions to market while adhering to stringent GMP standards. With a proven track record in transitioning consumer pharmaceuticals to Rx-to-OTC switches and developing various dosage forms, Rohinton is dedicated to improving the lives of patients through innovative medical device and pharmaceutical solutions. His commitment to excellence and innovation continues to drive InspiRx's mission to deliver transformative therapies that address unmet medical needs in respiratory health.
